Ebola: First Participant Vaccinated as DRC Begins Phase 2/3 Trial Against Deadly Bundibugyo Virus
The Democratic Republic of the Congo (DRC) has commenced a pivotal Phase 2/3 clinical trial to determine whether vaccine candidates can protect against the deadly Bundibugyo virus, following the vaccination of the first participant in Bunia. The post Ebola: First Participant Vaccinated as DRC Begins Phase 2/3 Trial Against Deadly Bundibugyo Virus appeared first on THEWILL NEWS MEDIA .
AI summary
The Democratic Republic of the Congo (DRC) has commenced a pivotal Phase 2/3 clinical trial to determine whether vaccine candidates can protect against the deadly Bundibugyo virus, following the vaccination of the first participant in Bunia.
The post
Ebola: First Participant Vaccinated as DRC Begins Phase 2/3 Trial Against Deadly Bundibugyo Virus
appeared first on
THEWILL NEWS MEDIA
.
Follow the story
About this article
- Length
- 59 words · 1 min read
- Published
- October 23, 2026
- Byline
- Felix Ifijeh
- Source
- THEWILL NEWS